D-0059-2023 Class III Terminated
FDA drug recall D-0059-2023 was initiated by Aadi Bioscience on Oct 13, 2022 and is designated Class III. Reason for recall: Failed Stability Specifications The recall status is terminated (terminated Mar 16, 2023). Affected quantity: 2,333 vials.
Recall details
- Product Type
- Drugs
- Report Date
- Nov 23, 2022
- Initiation Date
- Oct 13, 2022
- Termination Date
- Mar 16, 2023
- Voluntary/Mandated
- Voluntary: Firm initiated
- Product Quantity
- 2,333 vials
Product description
Fyarro (sirolimus protein-bound particles for injectable suspension (albumin-bound), 100 mg per vial, NDC 80803-153-50, manufactured for Aadi Bioscience, Inc, CA.
Reason for recall
Failed Stability Specifications
Distribution pattern
Within the U.S Market - PA, AL, KY, TN
Code information
Lot# 6025701, Expiration Date: 31MAR2023, 100mg/vial, 50 ml single use vial, NDC 80803-153-50.
Source
- Dataset
- openFDA drug recall enforcement reports
- FDA record
- This recall in openFDA (JSON)
- Enforcement Report
- Search FDA's Enforcement Report for D-0059-2023
- openFDA file date
- Nov 19, 2026
- Loaded by RegDataLab
- Nov 20, 2026
Need the full FDA record for Aadi Bioscience? Ask Claude or ChatGPT with the RegDataLab connector and get every site's inspections, Form 483s, warning letters, recalls and import alerts, each with a link to the FDA source. The API key is free: no card.